Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story
Executive Summary
Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.
You may also be interested in...
Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story (Part II)
In Part II of Medtech Insight’s extensive interview, Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, talked about the company’s vision for electrophysiology beyond the first generation of pulsed field ablation and the company’s commitment to improving diversity and inclusion.
Minute Insight: Pulsed AF Trial Of Medtronic’s PulseSelect PFA System Completes Enrollment
PULSED AF is a 500-patient pivotal trial of Medtronic’s PulseSelect PFA system for treating both paroxysmal and persistent atrial fibrillation in patients who have not responded to drugs.
Galaxy Gets $18M To Advance Centauri Pulsed Field Ablation System
ATP, a venture capital firm focused on life sciences, is providing the series A round to help Galaxy complete European and Canadian trials of its Centauri pulsed field ablation technology to treat atrial fibrillation.